Payment overview · 2025
General Payments
$4,640.66
163 reported records · 13 companies
Healthcare provider profile · identity verified
Ian Guerrero, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KAPOLEI, HI · NPI 1639604341
Verified facts
What the public records show
CMS Open Payments records show Ian Guerrero, M.D. received $4,640.66 in general payments during 2025 across 163 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Eliquis, Farxiga, Jardiance, Kerendia, Krystexxa, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Krystexxa by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arikayce by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,135.77 | 24.5% | 29 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $751.35 | 16.2% | 27 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $492.76 | 10.6% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $447.86 | 9.7% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $353.80 | 7.6% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $353.65 | 7.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $292.07 | 6.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $235.36 | 5.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $157.17 | 3.4% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $143.14 | 3.1% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $129.45 | 2.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.97 | 2.0% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $53.31 | 1.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,640.66 | 163 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $492.76 | 23 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $378.01 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $374.89 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $353.80 | 16 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $339.84 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $306.45 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $267.65 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $235.36 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $228.65 | 9 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $218.56 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $187.70 | 10 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $116.35 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.34 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $112.81 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $110.36 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $108.16 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $101.66 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $94.97 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.09 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $89.20 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $69.38 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.75 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $56.92 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $53.31 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.38 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $49.01 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 36 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 81 | exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 30 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 57 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
81 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 27 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 502 | 278 |
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 262 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 126 |
| Metformin Hcl Er | Metformin Hcl | 175 | 102 |
| Azithromycin | Azithromycin | 157 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 66 |
| Alendronate Sodium | Alendronate Sodium | 120 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 65 |
| Prednisone | Prednisone | 116 | 96 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 113 | 60 |
| Jardiance | Empagliflozin | 112 | 52 |
| Allopurinol | Allopurinol | 102 | 55 |
| Farxiga | Dapagliflozin Propanediol | 100 | 57 |
| Metformin Hcl | Metformin Hcl | 92 | 50 |
| Ozempic | Semaglutide | 92 | 28 |
| Simvastatin | Simvastatin | 92 | 48 |
| Cefdinir | Cefdinir | 91 | 77 |
| Gabapentin | Gabapentin | 91 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 61 |
| Kerendia | Finerenone | 81 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 27 |
| Furosemide | Furosemide | 76 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 47 |
| Meclizine Hcl | Meclizine Hcl | 68 | 53 |
| Omeprazole | Omeprazole | 68 | 46 |
| Finasteride | Finasteride | 66 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 35 |
| Clobetasol Propionate | Clobetasol Propionate | 55 | 32 |
| Colchicine | Colchicine | 52 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 27 |
| Linzess | Linaclotide | 50 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 11 |
| Famotidine | Famotidine | 46 | 29 |
| Alprazolam | Alprazolam | 42 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 19 |
| Carvedilol | Carvedilol | 41 | 22 |
| Myrbetriq | Mirabegron | 37 | 11 |
| Eliquis | Apixaban | 36 | 22 |
| Januvia | Sitagliptin Phosphate | 35 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 16 |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | 14 |
| Krystexxa | Pegloticase | 29 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 28 | 14 |
| Lisinopril | Lisinopril | 28 | 19 |
| Trazodone Hcl | Trazodone Hcl | 28 | 16 |
| Xarelto | Rivaroxaban | 27 | 11 |
| Mirtazapine | Mirtazapine | 26 | 14 |
| Mupirocin | Mupirocin | 26 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Vascepa | Icosapent Ethyl | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Glipizide | Glipizide | 23 | 14 |
| Halobetasol Propionate | Halobetasol Propionate | 23 | 13 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 22 |
| Montelukast Sodium | Montelukast Sodium | 22 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | 13 |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 14 |
| Valsartan | Valsartan | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | 14 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | 13 |
| Memantine Hcl | Memantine Hcl | 20 | 14 |
| Spironolactone | Spironolactone | 20 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 18 |
| Tradjenta | Linagliptin | 20 | 12 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Prolia | Denosumab | 19 | 16 |
| Rifampin | Rifampin | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 13 |
| Naproxen | Naproxen | 17 | 17 |
| Risperidone | Risperidone | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | 11 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Ethambutol Hcl | Ethambutol Hcl | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,640.66 · 163 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CREON, ELIQUIS, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, LOKELMA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SKYRIZI, TEPEZZA, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error